SCHEMBL76267

SCHEMBL76267

C#CCOC(C(=O)OC)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
SLC6A2 P23975 1/20 0.39
CNR2 P34972 1/20 0.38
UTS2R Q9UKP6 4/20 0.38
NR3C2 P08235 1/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
BRD4 O60885 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77404 0.88 NPC1 (0.40) L3MBTL1CNR2MEN1KMT2ABRD4
SCHEMBL76511 0.87 PPARG (0.37) L3MBTL1MEN1KMT2ABRD4HDAC4
SCHEMBL5917972 0.83 PPARG (0.36) CNR2MEN1KMT2ABRD4HDAC4
SCHEMBL75610 0.83 PPARG (0.46) MEN1KMT2A
SCHEMBL85757 0.83 PPARG (0.35) L3MBTL1MEN1KMT2ABRD4
Hydrochloric Acid SCHEMBL5918049 0.82 PPARG (0.44) UTS2RMEN1KMT2A
SCHEMBL1154849 0.77 L3MBTL1 (0.49) L3MBTL1SLC6A4SLC6A3SLC6A2UTS2R
SCHEMBL11359954 0.73 L3MBTL1 (0.46) L3MBTL1SLC6A4SLC6A3SLC6A2UTS2R
SCHEMBL5918040 0.73 L3MBTL1 (0.46) L3MBTL1SLC6A4SLC6A3SLC6A2CNR2
SCHEMBL14558224 0.73 ADRB2 (0.41) SLC6A4SLC6A3SLC6A2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
EP-1919857-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF Syngeta Participations AG (CH) 2008-05-14 EP disclosed
WO-2007020381-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed
WO-2007020381-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed
US-20060041144-A1 Phenylpyridine compound and fungicidal compostion containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-02-23 US disclosed
EP-1541557-A1 PHENYLPYRIDINE COMPOUND AND BACTERICIDAL COMPOSITION CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060041144-A1 Phenylpyridine compound and fungicidal compostion containing the same CBR3, CYP1A1, PAH L3MBTL1 222/4885SLC6A4 2841/4885SLC6A3 2788/4885
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof OPRM1, OPRD1, ADRA1D L3MBTL1 619/4885SLC6A4 301/4885SLC6A3 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.